Addex Therapeutics has signed an option and collaboration agreement with Sinntaxis AB.
Recovery after a stroke or brain injury depends on the brain’s ability to form new connections or reactivate existing ones. Research suggests that the metabotropic glutamate receptor 5 (mGlu5) plays a key role in brain plasticity and function. Inhibiting this receptor with negative allosteric modulators (NAMs) may help improve recovery.
The deal grants Addex exclusive rights to intellectual property related to the use of metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors in promoting recovery following brain injury.
As part of the agreement, Sinntaxis will carry out research to assess the potential of Addex’s compound, dipraglurant. This orally available mGlu5 negative allosteric modulator (NAM) is already a key clinical candidate within Addex’s portfolio.
The planned preclinical work will focus on evaluating dipraglurant’s potential in supporting functional recovery after brain damage, including from stroke or traumatic brain injury.
Addex has previously conducted clinical trials for dipraglurant in other indications, where the compound demonstrated good safety and selectivity towards the mGlu5 receptor. The collaboration with Sinntaxis will help further validate the drug's role in neuroplasticity and its potential in aiding recovery post-brain injury.
The agreement includes an undisclosed option fee payable by Addex to access Sinntaxis’ patent rights covering the use of mGlu5 NAMs in treating neurological damage resulting from stroke or other forms of trauma. Sinntaxis will also contribute to the design of future clinical trials based on the outcome of the ongoing preclinical studies.
This collaboration aims to advance dipraglurant as a potential treatment for patients recovering from brain injury, addressing a significant area of unmet medical need.